Dolutegravir

The standard dosage of Dolutegravir for most adults and adolescents (weighing at least 40 kg) who have not previously taken an integrase inhibitor is 50 mg taken once daily.

However, for patients who are taking certain interacting medications (such as rifampin, efavirenz, or carbamazepine) or for those who have documented resistance to other integrase inhibitors, the dosage is typically increased to 50 mg taken twice daily. Your healthcare provider will determine the frequency based on your treatment history and the results of resistance testing (genotyping).

Dolutegravir is approved for use in pediatric patients as young as 4 weeks of age, provided they weigh at least 3 kg (approximately 6.6 lbs). The dosage for children is strictly weight-based:

• 3 kg to <6 kg: 5 mg once daily (using dispersible tablets).
• 6 kg to <10 kg: 15 mg once daily.
• 10 kg to <14 kg: 20 mg once daily.
• 14 kg to <20 kg: 25 mg once daily.
• 20 kg and above: 50 mg once daily (or the adult dose).

Healthcare providers must carefully monitor a child's weight to adjust the dose as they grow. The dispersible tablets and the regular film-coated tablets are not always interchangeable on a milligram-for-milligram basis; always follow the specific formulation instructions provided by the pharmacist.

Renal Impairment

For patients with mild, moderate, or severe renal impairment (kidney disease), no dosage adjustment is typically required for Dolutegravir. However, caution is advised for patients with severe renal impairment who also have integrase inhibitor resistance, as data in this specific sub-population is limited.

Hepatic Impairment

No dosage adjustment is necessary for patients with mild to moderate hepatic impairment (Child-Pugh Class A or B). Dolutegravir has not been extensively studied in patients with severe hepatic impairment (Child-Pugh Class C); therefore, its use in these individuals is generally not recommended unless the benefits clearly outweigh the risks.

Elderly Patients

Clinical trials of Dolutegravir did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

• Consistency: Take Dolutegravir at the same time every day to maintain a steady level of the medication in your bloodstream. This helps prevent the virus from developing resistance.
• Food: It can be taken with or without food. However, if you have integrase inhibitor resistance, your doctor may recommend taking it with food to increase absorption.
• Swallowing: Regular tablets should be swallowed whole. Do not crush or chew them. Dispersible tablets (Tivicay PD) should be dissolved in the provided amount of water and swallowed immediately.
• Storage: Store the medication at room temperature (68°F to 77°F) in its original container. Keep the container tightly closed and protect it from moisture.

If you miss a dose of Dolutegravir, take it as soon as you remember. However, if it is within 4 hours of your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take two doses at once to make up for a missed one. Frequent missed doses can lead to 'treatment failure,' where the virus becomes resistant to the medication.

There is limited experience with Dolutegravir overdose. In the event of an overdose, contact your local poison control center or seek emergency medical attention immediately. Symptoms of overdose may include severe versions of common side effects, such as extreme dizziness or nausea. There is no specific antidote for Dolutegravir; treatment consists of general supportive care and monitoring of vital signs.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this can cause the virus to multiply rapidly.

Most people tolerate Dolutegravir well, but some may experience side effects, especially during the first few weeks of treatment. Common side effects include:

• Insomnia: Difficulty falling or staying asleep is one of the most frequently reported issues. This often improves over time as the body adjusts to the medication.
• Headache: Mild to moderate headaches may occur. Over-the-counter pain relief may be suggested by your doctor if these persist.
• Fatigue: A general feeling of tiredness or lack of energy.
• Nausea and Diarrhea: Mild gastrointestinal upset is common when starting any antiretroviral therapy.

• Dizziness: Some patients report a feeling of lightheadedness or vertigo.
• Abnormal Dreams: Vivid or unusual dreams have been reported, though less frequently than with other HIV medications like efavirenz.
• Vomiting and Abdominal Pain: More significant GI distress that may require medical consultation if it leads to dehydration.
• Rash: A mild skin rash may develop. If the rash is severe or accompanied by fever, seek medical attention immediately.

• Depression and Anxiety: While rare, some patients have reported mood changes, including suicidal ideation, particularly those with a pre-existing history of psychiatric illness.
• Myalgia: Muscle pain or weakness.
• Renal Insufficiency: Changes in kidney function markers, though Dolutegravir specifically affects creatinine secretion without necessarily decreasing actual glomerular filtration rate.

> Warning: Stop taking Dolutegravir and call your doctor immediately if you experience any of these serious symptoms:

• Hypersensitivity Reactions: This is a medical emergency. Symptoms include a severe skin rash, fever, general malaise, extreme tiredness, muscle or joint aches, blisters, oral lesions, or swelling of the face, lips, and tongue. If a hypersensitivity reaction occurs, Dolutegravir must be stopped immediately and never restarted.
• Hepatotoxicity (Liver Damage): Signs include yellowing of the skin or eyes (jaundice), dark-colored urine, light-colored stools, nausea, vomiting, or pain on the right side of the stomach area. Patients with Hepatitis B or C are at higher risk for liver enzyme elevations.
• Immune Reconstitution Inflammatory Syndrome (IRIS): As your immune system gets stronger, it may start to fight infections that were already in your body but hidden. This can cause an inflammatory response. Symptoms depend on the underlying infection (e.g., pneumonia, fungal infections).

With prolonged use of Dolutegravir, healthcare providers monitor for:

• Weight Gain: Recent clinical studies (such as the ADVANCE trial) have shown that INSTIs, including Dolutegravir, are associated with more significant weight gain than older drug classes, particularly when combined with tenofovir alafenamide (TAF).
• Metabolic Changes: While generally considered 'lipid-neutral,' long-term monitoring of cholesterol and blood sugar levels is standard practice.
• Bone Density: While less impactful than some other HIV drugs, bone health is always a consideration in long-term HIV management.

As of the current 2026 clinical guidelines, there are no FDA black box warnings specifically for Dolutegravir single-entity products. However, it is important to note that many combination products containing Dolutegravir (like Triumeq) carry black box warnings for other components (such as Abacavir's risk for hypersensitivity). Always check the specific labeling for the exact product you are prescribed.

Report any unusual symptoms or changes in your health to your healthcare provider immediately. Early detection of side effects is key to maintaining a successful long-term treatment plan.

Dolutegravir is a powerful medication that requires careful medical supervision. It does not cure HIV infection or AIDS, but it helps control the virus so you can live a longer, healthier life. It is crucial to understand that even while taking this medication, you can still transmit HIV to others through sexual contact or blood contamination, although the risk is significantly reduced when the viral load is 'undetectable.'

No FDA black box warnings for Dolutegravir (Tivicay). However, patients should be aware that combination products containing Dolutegravir may have different warning profiles.

• Hypersensitivity Reactions: There is a risk of severe and potentially life-threatening allergic reactions. If you develop a rash along with systemic symptoms like fever or muscle aches, you must stop the drug immediately. A delay in stopping Dolutegravir after the onset of hypersensitivity may result in a life-threatening reaction.
• Hepatotoxicity: Liver injury has been reported in patients receiving Dolutegravir. This is more common in patients with a history of Hepatitis B or C infection. Your doctor will perform blood tests to check your liver function before and during treatment.
• Neural Tube Defects: Early in the drug's history, there was a concern regarding the risk of neural tube defects (birth defects of the brain and spine) when taken at the time of conception. Current data suggests this risk is much lower than initially feared, but it remains an important discussion point for individuals of childbearing potential.
• Immune Reconstitution Inflammatory Syndrome (IRIS): This condition occurs when the immune system recovers and begins to respond to previously undiagnosed 'opportunistic' infections. This can lead to a sudden onset of symptoms shortly after starting HIV therapy.

To ensure Dolutegravir is safe and effective for you, your healthcare provider will require regular laboratory monitoring:

• Viral Load (HIV-1 RNA): To ensure the medication is suppressing the virus.
• CD4+ Cell Count: To monitor the health of your immune system.
• Liver Function Tests (LFTs): Specifically ALT, AST, and bilirubin levels, especially in patients co-infected with Hepatitis.
• Serum Creatinine: Dolutegravir can increase creatinine levels by inhibiting a specific transporter (OCT2) in the kidneys. This usually does not indicate a decrease in actual kidney function, but your doctor needs to monitor it to distinguish it from actual kidney damage.

Dolutegravir may cause dizziness or fatigue in some individuals. If you experience these side effects, use caution when driving or operating heavy machinery until you know how the medication affects you.

There is no direct contraindication between Dolutegravir and alcohol. However, excessive alcohol consumption can strain the liver and may make it harder to remember to take your medication on time. Discuss your alcohol intake with your doctor to ensure it does not interfere with your treatment goals.

Never stop taking Dolutegravir without consulting your doctor. Stopping HIV medication causes the viral load to rebound quickly, which can damage your immune system and lead to the development of drug-resistant strains of the virus. If you must stop the medication due to a side effect, your doctor will provide a plan to transition you to a different therapy.

> Important: Discuss all your medical conditions, including liver disease, kidney disease, and pregnancy plans, with your healthcare provider before starting Dolutegravir.

Certain drugs must never be taken with Dolutegravir because they can cause life-threatening heart rhythm problems or severely reduce the effectiveness of the HIV treatment:

• Dofetilide: Dolutegravir increases the levels of dofetilide (an anti-arrhythmic) in the blood by inhibiting the OCT2 transporter. High levels of dofetilide can cause 'Torsades de Pointes,' a fatal heart rhythm disturbance.

• Metformin: Dolutegravir can increase the concentration of metformin (a diabetes medication). This may increase the risk of lactic acidosis. Your doctor may need to adjust your metformin dose.
• Anticonvulsants: Drugs like carbamazepine, phenytoin, and phenobarbital can significantly lower the levels of Dolutegravir in your blood, making it less effective. Often, the dose of Dolutegravir must be increased to 50 mg twice daily if these drugs are necessary.
• Rifampin: This antibiotic used for tuberculosis significantly induces the enzymes that break down Dolutegravir. A twice-daily dose of Dolutegravir is required when taking rifampin.

• Cation-containing Antacids and Supplements: Antacids containing aluminum, magnesium, or calcium, as well as iron or zinc supplements, can bind to Dolutegravir in the digestive tract and prevent it from being absorbed.
• Management Strategy: Take Dolutegravir at least 2 hours before or 6 hours after taking these supplements. Alternatively, Dolutegravir and supplements containing calcium or iron can be taken together if taken with food.

• High-Fat Meals: As mentioned, high-fat food increases the absorption of Dolutegravir. While not required for most patients, it is a useful strategy for those with some degree of drug resistance.
• Grapefruit: Unlike many other HIV drugs, Dolutegravir does not have a significant interaction with grapefruit juice.

• St. John's Wort: This herbal supplement is a potent inducer of drug-metabolizing enzymes. It can lower the levels of Dolutegravir in your blood to sub-therapeutic levels, leading to treatment failure and viral resistance. It should be avoided.
• Multivitamins: These often contain iron or zinc. Follow the same timing rules as described for antacids.

• Serum Creatinine: Dolutegravir consistently increases serum creatinine levels within the first few weeks of treatment. This is due to the inhibition of the tubular secretion of creatinine and does not reflect a change in the actual glomerular filtration rate (GFR). This can lead to a 'false' appearance of kidney decline if the clinician is not aware of this specific pharmacological effect.

For each interaction, the primary mechanism involves either the induction/inhibition of the UGT1A1 enzyme or the inhibition of the OCT2 renal transporter. The clinical consequence is either increased drug toxicity (as with Metformin or Dofetilide) or reduced efficacy of the HIV treatment (as with Rifampin or Antacids).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter vitamins and minerals.

There are two primary scenarios where Dolutegravir must never be used:

1. 1Hypersensitivity: If a patient has had a previous clinically significant hypersensitivity reaction to Dolutegravir, they must not take it again. Re-exposure can lead to a rapid and life-threatening systemic reaction.
2. 2Co-administration with Dofetilide: Because Dolutegravir inhibits the renal transporter (OCT2) responsible for clearing dofetilide, the resulting increase in dofetilide levels creates an unacceptable risk of fatal cardiac arrhythmias. This is a hard contraindication with no 'workaround' other than choosing a different anti-arrhythmic or a different HIV medication.

• Severe Hepatic Impairment: Because the drug is primarily metabolized by the liver, patients with Child-Pugh Class C liver disease may experience unpredictable drug levels. Use in this population requires a careful risk-benefit analysis and intensive monitoring.
• Integrase Inhibitor Resistance: While Dolutegravir is effective against some strains resistant to raltegravir, its efficacy is significantly reduced if certain specific mutations (like Q148 plus two or more mutations) are present. In these cases, it is relatively contraindicated as a once-daily therapy.

There is no evidence of broad cross-sensitivity between Dolutegravir and other classes of HIV medications (like NRTIs or Protease Inhibitors). However, if a patient has reacted to other integrase inhibitors (like Cabotegravir), healthcare providers should exercise extreme caution, although cross-reactivity is not guaranteed.

> Important: Your healthcare provider will evaluate your complete medical history, including any previous drug allergies and current heart health, before prescribing Dolutegravir.

• FDA/TGA Status: Dolutegravir is widely used in pregnancy.
• Clinical Data: In 2018, data from the Tsepamo study in Botswana suggested a potential link between Dolutegravir use at the time of conception and an increased risk of neural tube defects (NTDs). However, as more data was collected (up to 2024), the risk was found to be much lower (approximately 0.11% vs 0.07% in the general population).
• Current Guidelines: Both the WHO and the DHHS now recommend Dolutegravir as a preferred treatment option for individuals of childbearing potential and throughout pregnancy, as the benefits of superior viral suppression and maternal health outweigh the small potential risk of NTDs. Patients should discuss folic acid supplementation with their doctor, as this can help prevent NTDs.

• Passage into Milk: Dolutegravir is excreted in human breast milk in small amounts.
• Recommendations: In resource-rich settings (like the US or Europe) where clean water and infant formula are available, the CDC and other health authorities traditionally recommended that individuals with HIV avoid breastfeeding to eliminate the risk of transmission. However, updated 2024/2025 guidelines emphasize shared decision-making. If the parent's viral load is consistently undetectable, the risk of transmission via breast milk is extremely low (<1%).

Dolutegravir is approved for pediatric patients weighing at least 3 kg. It is one of the few integrase inhibitors with a dispersible tablet formulation (Tivicay PD) that allows for dosing in infants as young as 4 weeks. It has been shown to be safe and effective in children, with side effects similar to those seen in adults. It is not currently approved for infants weighing less than 3 kg.

Older adults may be at higher risk for side effects due to age-related declines in kidney or liver function. Furthermore, geriatric patients are more likely to be taking medications for hypertension, diabetes, or heart disease, increasing the risk of drug-drug interactions. Clinical monitoring should focus on renal function and potential weight gain.

No dose adjustment is needed for patients with kidney disease. However, for those on dialysis, Dolutegravir should be administered after the dialysis session, as it is not significantly removed by the procedure.

Patients with mild-to-moderate liver disease can take the standard dose. Those with severe cirrhosis (Child-Pugh C) should generally avoid Dolutegravir due to a lack of safety data in that specific population.

> Important: Special populations require individualized medical assessment and frequent monitoring to ensure the safest possible treatment outcomes.

Dolutegravir is an Integrase Strand Transfer Inhibitor (INSTI). The HIV-1 integrase enzyme is responsible for inserting the viral genome into the host cell DNA. This enzyme requires two divalent metal cations (magnesium) at its active site to function. Dolutegravir's chemical structure allows it to bind to these metal ions and the viral DNA simultaneously. This 'chelating' action locks the enzyme in an inactive state, preventing the 'strand transfer' step where the viral DNA is joined to the human DNA. Because human cells do not use an equivalent integration process for their own DNA, the drug is highly selective for the virus.

• Antiviral Activity: Dolutegravir shows potent activity against HIV-1, with an IC50 (concentration needed to inhibit 50% of viral growth) in the sub-nanomolar range.
• Onset: Viral load reduction typically begins within days of the first dose, with many patients achieving an 'undetectable' status within 4 to 8 weeks.
• Resistance: It has a 'high genetic barrier,' meaning the virus must develop multiple specific mutations to become resistant to Dolutegravir, unlike first-generation INSTIs which could fail with a single mutation.

| Parameter | Value |

|---|---|

| Bioavailability | Increased with food (not quantified as absolute %) |

| Protein Binding | >99% |

| Half-life | ~14 hours |

| Tmax | 2 - 3 hours |

| Metabolism | UGT1A1 (Primary), CYP3A4 (Minor) |

| Excretion | Fecal 53%, Renal 31% |

• Molecular Formula: C20H18F2N3O5Na (as sodium salt)
• Molecular Weight: 441.36 g/mol
• Solubility: Slightly soluble in water.
• Structure: It features a tricyclic core that is optimized for deep binding within the integrase-DNA complex, which contributes to its long 'dissociation half-life' (how long it stays stuck to the enzyme).

Dolutegravir belongs to the Integrase Strand Transfer Inhibitor (INSTI) class. Other drugs in this class include Raltegravir (Isentress), Elvitegravir (Vitekta), Bictegravir (in Biktarvy), and Cabotegravir (Vocabria/Vocabria).